Related references
Note: Only part of the references are listed.VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy
S. Lu et al.
ANNALS OF ONCOLOGY (2022)
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Laura Keller et al.
BRITISH JOURNAL OF CANCER (2021)
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients withEGFR-mutated,MET-amplified advanced non-small-cell lung cancer
Jin-Ji Yang et al.
INVESTIGATIONAL NEW DRUGS (2021)
Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations
Antonio Passaro et al.
JOURNAL OF THORACIC ONCOLOGY (2021)
P51.01 Tepotinib Plus an EGFR TKI in Patients with EGFR-mutant NSCLC and Resistance to EGFR TKIs Due to MET Amplification (METamp)
C.K. Liam et al.
Journal of Thoracic Oncology (2021)
A Large Real-World Study on the Effectiveness of the Combined Inhibition of EGFR and MET in EGFR-Mutant Non-Small-Cell Lung Cancer After Development of EGFR-TKI Resistance
Li Liu et al.
FRONTIERS IN ONCOLOGY (2021)
FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study
J.M. Bauml et al.
Journal of Thoracic Oncology (2021)
P76.46 First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
W. Tan et al.
Journal of Thoracic Oncology (2021)
P85.02 NGS could not Replace FISH Regarding to MET Amplification as an Optimal Biomarker
L. Peng et al.
Journal of Thoracic Oncology (2021)
Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Beung-Chul Ahn et al.
CANCERS (2021)
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903
K. Ito et al.
ESMO OPEN (2021)
Phase I/II Study of Capmatinib Plus Erlotinib in Patients With MET-Positive Non-Small-Cell Lung Cancer
Caroline E. McCoach et al.
JCO PRECISION ONCOLOGY (2021)
Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer
Peter T. Harrison et al.
SEMINARS IN CANCER BIOLOGY (2020)
First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
Gerald S. Falchook et al.
CLINICAL CANCER RESEARCH (2020)
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer
Adam J Schoenfeld et al.
CLINICAL CANCER RESEARCH (2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Sequist et al.
LANCET ONCOLOGY (2020)
Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial
Yi-Long Wu et al.
LANCET RESPIRATORY MEDICINE (2020)
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Charles Pottier et al.
CANCERS (2020)
Mechanisms of osimertinib resistance and emerging treatment options
Sabine Schmid et al.
LUNG CANCER (2020)
Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
Nitin Roper et al.
CELL REPORTS MEDICINE (2020)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib
Yuxin Mu et al.
TARGETED ONCOLOGY (2019)
MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
Qiming Wang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
Alessandro Leonetti et al.
BRITISH JOURNAL OF CANCER (2019)
Comparison of in situ and extraction-based methods for the detection of MET amplifications in solid tumors
Carina Heydt et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2019)
Antitumor activity of histone deacetylase inhibitor chidamide alone or in combination with epidermal growth factor receptor tyrosine kinase inhibitor icotinib in NSCLC
Ningning Zhang et al.
JOURNAL OF CANCER (2019)
Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer
N. Guibert et al.
ANNALS OF ONCOLOGY (2018)
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients
Zhe Yang et al.
CLINICAL CANCER RESEARCH (2018)
Clinical analysis by next-generation sequencing for NSCLC patients with &ITMET&IT amplification resistant to osimertinib
Yubo Wang et al.
LUNG CANCER (2018)
Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer
Shang-Gin Wu et al.
MOLECULAR CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
Chia-Chi Lin et al.
LANCET RESPIRATORY MEDICINE (2018)
Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer
Yi-Long Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion
Zofia Piotrowska et al.
CANCER DISCOVERY (2018)
Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T79OM-Positive Lung Cancer and Acquired Resistance to Osimertinib
Geoffrey R. Oxnard et al.
JAMA ONCOLOGY (2018)
LBA8Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
B C Cho et al.
ANNALS OF ONCOLOGY (2018)
1377OPhase II study of tepotinib + gefitinib (TEP+GEF) in MET-positive (MET+)/epidermal growth factor receptor (EGFR)-mutant (MT) non-small cell lung cancer (NSCLC)
Y Cheng et al.
ANNALS OF ONCOLOGY (2018)
LBA51Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study
V A Papadimitrakopoulou et al.
ANNALS OF ONCOLOGY (2018)
Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC
Xiuning Le et al.
CLINICAL CANCER RESEARCH (2018)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer?
Yi-Long Wu et al.
CANCER TREATMENT REVIEWS (2017)
Common Fluorescence In Situ Hybridization Applications in Cytology
Spasenija Savic et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis
Sinead A. Noonan et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
Response assessment criteria for brain metastases: proposal from the RANO group
Nancy U. Lin et al.
LANCET ONCOLOGY (2015)
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation- positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean-Charles Soria et al.
LANCET ONCOLOGY (2015)
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
Darren A. E. Cross et al.
CANCER DISCOVERY (2014)
EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors
Friedhelm Bladt et al.
CLINICAL CANCER RESEARCH (2013)
Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC
Alexa B. Turke et al.
CANCER CELL (2010)
Increased MET Gene Copy Number Negatively Affects Survival of Surgically Resected Non-Small-Cell Lung Cancer Patients
Federico Cappuzzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Review: Predictive and prognostic markers for epidermal growth factor receptor inhibitor therapy in non-small cell lung cancer
Nir Peled et al.
Therapeutic Advances in Medical Oncology (2009)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Share Paper
